By: Ling Xu, Li Wei, Renzhong Zhang, Jinyu Li, Fei Xie
Keywords: Pterygium; pranoprofen; tobramycin and dexamethasone; tears; inflammatory factors.
DOI : 10.36721/PJPS.2025.38.3.REG.14191.1
Abstract: Pterygium, characterized by conjunctival overgrowth onto the cornea, poses recurrence risks post-surgery. This study evaluated the efficacy of pranoprofen + tobramycin/dexamethasone vs. tobramycin/dexamethasone alone in 108 patients (55 observation, 53 control) randomized post-pterygium surgery (March 2023–March 2024). Outcomes included ocular pain (VAS), tear inflammatory factors (IgE, IL-6, IL-8, TNF-?), tear stability (BUT, CESS, SIt), quality of life (OSDI), adverse events and recurrence at 1 day, 1 week and 4 weeks postoperatively. At 1 week, the observation group reported superior pain relief (P<0.05), with both groups achieving pain-free status by 4 weeks. Inflammatory markers and OSDI scores were significantly lower in the observation group at 1 and 4 weeks (P<0.05), alongside improved tear stability (P<0.05). No adverse events occurred. At 6-month follow-up, recurrence rates were comparable (1.85% vs. 9.43%, P>0.05), though the observation group trended lower. In conclusion, Pranoprofen + tobramycin/dexamethasone offers enhanced pain control, tear function and anti-inflammatory effects, with a potential recurrence-lowering benefit, supporting its clinical utility in pterygium management.
[View Complete Article]
